Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
BPMCBlueprint Medicines(BPMC) Zacks Investment Research·2024-05-02 21:11

Blueprint Medicines (BPMC) came out with a quarterly loss of 1.32pershareversustheZacksConsensusEstimateofalossof1.32 per share versus the Zacks Consensus Estimate of a loss of 1.64. This compares to loss of 2.15pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof19.512.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 19.51%. A quarter ago, it was expected that this cancer drug developer would post a loss of 2.04 per share when it actually produced a loss of $1.82, delivering a surprise of 10.78%. Over the last four quarters, the ...